191 related articles for article (PubMed ID: 11124107)
21. FK506 (tacrolimus) in the treatment of steroid-resistant acute graft-versus-host disease in children undergoing bone marrow transplantation.
Koehler MT; Howrie D; Mirro J; Neudorf S; Blatt J; Corey S; Wollman M; Kelly-Ekeroth V; Reyes J
Bone Marrow Transplant; 1995 Jun; 15(6):895-9. PubMed ID: 7581088
[TBL] [Abstract][Full Text] [Related]
22. Mycophenolate-based graft versus host disease prophylaxis is not inferior to methotrexate in myeloablative-related donor stem cell transplantation.
Hamad N; Shanavas M; Michelis FV; Uhm J; Gupta V; Seftel M; Kuruvilla J; Lipton JH; Messner HA; Kim DD
Am J Hematol; 2015 May; 90(5):392-9. PubMed ID: 25615933
[TBL] [Abstract][Full Text] [Related]
23. Use of mycophenolate mofetil in patients received allogeneic hematopoietic stem cell transplantation in Japan.
Iida M; Fukuda T; Ikegame K; Yoshihara S; Ogawa H; Taniguchi S; Takami A; Abe Y; Hino M; Etou T; Ueda Y; Yujiri T; Matsui T; Okamura A; Tanaka J; Atsuta Y; Kodera Y; Suzuki R
Int J Hematol; 2011 Apr; 93(4):523-531. PubMed ID: 21465117
[TBL] [Abstract][Full Text] [Related]
24. Mycophenolate mofetil for treatment of steroid-refractory acute graft-versus-host disease after pediatric hematopoietic stem cell transplantation.
Inagaki J; Kodama Y; Fukano R; Noguchi M; Okamura J
Pediatr Transplant; 2015 Sep; 19(6):652-8. PubMed ID: 26103520
[TBL] [Abstract][Full Text] [Related]
25. Mycophenolate mofetil (MMF) as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplantation.
Busca A; Saroglia EM; Lanino E; Manfredini L; Uderzo C; Nicolini B; Messina C; Rabusin M; Miniero R
Bone Marrow Transplant; 2000 May; 25(10):1067-71. PubMed ID: 10828867
[TBL] [Abstract][Full Text] [Related]
26. Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation.
Hiraoka A; Ohashi Y; Okamoto S; Moriyama Y; Nagao T; Kodera Y; Kanamaru A; Dohy H; Masaoka T;
Bone Marrow Transplant; 2001 Jul; 28(2):181-5. PubMed ID: 11509936
[TBL] [Abstract][Full Text] [Related]
27. A high risk of life-threatening infectious complications in mycophenolate mofetil treatment for acute or chronic graft-versus-host disease.
Onishi C; Ohashi K; Sawada T; Nakano M; Kobayashi T; Yamashita T; Akiyama H; Sakamaki H
Int J Hematol; 2010 Apr; 91(3):464-70. PubMed ID: 20217287
[TBL] [Abstract][Full Text] [Related]
28. FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporin and/or other immunosuppressants. Japanese FK506 BMT Study Group.
Kanamaru A; Takemoto Y; Kakishita E; Dohy H; Kodera Y; Moriyama Y; Shibata A; Kasai M; Katoh S; Saitoh H
Bone Marrow Transplant; 1995 Jun; 15(6):885-9. PubMed ID: 7581086
[TBL] [Abstract][Full Text] [Related]
29. Steroid-refractory graft-vs.-host disease: past, present and future.
Carpenter PA; Sanders JE
Pediatr Transplant; 2003; 7 Suppl 3():19-31. PubMed ID: 12603689
[TBL] [Abstract][Full Text] [Related]
30. Tacrolimus as monotherapy or combined with minidose methotrexate for graft-versus-host disease prophylaxis after allogeneic peripheral blood stem cell transplantation: long-term outcomes.
Uberti JP; Ayash L; Braun T; Reynolds C; Silver S; Ratanatharathorn V
Bone Marrow Transplant; 2004 Sep; 34(5):425-31. PubMed ID: 15273705
[TBL] [Abstract][Full Text] [Related]
31. Nonmyeloablative transplants: preclinical and clinical results.
Sandmaier BM; McSweeney P; Yu C; Storb R
Semin Oncol; 2000 Apr; 27(2 Suppl 5):78-81. PubMed ID: 10877058
[TBL] [Abstract][Full Text] [Related]
32. Psoralen plus ultraviolet-A-bath photochemotherapy as an adjunct treatment modality in cutaneous chronic graft versus host disease.
Leiter U; Kaskel P; Krähn G; Gottlöber P; Bunjes D; Peter RU; Kerscher M
Photodermatol Photoimmunol Photomed; 2002 Aug; 18(4):183-90. PubMed ID: 12390673
[TBL] [Abstract][Full Text] [Related]
33. New strategies in the treatment of graft-versus-host disease.
Basara N; Blau IW; Willenbacher W; Kiehl MG; Fauser AA
Bone Marrow Transplant; 2000 May; 25 Suppl 2():S12-5. PubMed ID: 10933179
[TBL] [Abstract][Full Text] [Related]
34. Graft-versus-host disease after marrow transplantation.
Storb R
Prog Clin Biol Res; 1986; 224():139-57. PubMed ID: 3540990
[TBL] [Abstract][Full Text] [Related]
35. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
36. Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities.
Furlong T; Storb R; Anasetti C; Appelbaum FR; Deeg HJ; Doney K; Martin P; Sullivan K; Witherspoon R; Nash RA
Bone Marrow Transplant; 2000 Nov; 26(9):985-91. PubMed ID: 11100278
[TBL] [Abstract][Full Text] [Related]
37. Transplantation-Associated Thrombotic Microangiopathy in Patients Treated With Sirolimus and Cyclosporine as Salvage Therapy for Graft-Versus-Host Disease.
García-Martín P; Alarcón-Payer C; López-Fernández E; Moratalla L; Romero A; Sainz J; Ríos R; Jurado M
Ann Pharmacother; 2015 Sep; 49(9):986-94. PubMed ID: 26160968
[TBL] [Abstract][Full Text] [Related]
38. Current and novel therapies in acute GVHD.
Ho VT; Cutler C
Best Pract Res Clin Haematol; 2008 Jun; 21(2):223-37. PubMed ID: 18503988
[TBL] [Abstract][Full Text] [Related]
39. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Gruessner RW
Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
[TBL] [Abstract][Full Text] [Related]
40. Emerging therapies for graft-versus-host disease.
Jacobsohn DA
Expert Opin Emerg Drugs; 2003 Nov; 8(2):323-38. PubMed ID: 14661992
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]